About SUNSHINE PHARMA Company

Guangdong Dongyangguang Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company" or "Dongyangguang Pharma"), together with its subsidiaries (collectively referred to as "the Group" or "we"), is a comprehensive, R&D-driven pharmaceutical company rooted in China and oriented toward the global market. The Company boasts end-to-end capabilities spanning research and development ("R&D"), manufacturing, and sales, with a strong focus on three key therapeutic areas: infectious diseases, chronic diseases, and oncology. It has established a diversified, robust, and commercially promising pipeline of innovative drugs in development, along with comprehensive in-house R&D capabilities, and has built a full-spectrum R&D platform and technologies that cover the entire lifecycle of both small-molecule and biologic drug development. The Company's R&D team comprises more than 1,100 professionals, including scientists with extensive experience at multinational pharmaceutical companies and highly skilled pharmaceutical talent with proven track records in R&D execution. The Company has been recognized with numerous national-level designations and provincial awards, such as National Key Laboratory status, National Intellectual Property Demonstration Enterprise designation, a Postdoctoral Research Station, and the First Prize for Scientific and Technological Progress of Guangdong Province, among others. The Company was founded on December 29, 2003, in Dongguan City, Guangdong Province, China. To date, it has nearly 22 years of operating history, with leading positions in both pharmaceutical sales performance and R&D capabilities within the domestic pharmaceutical industry. In 2005, the Company established an R&D Institute dedicated to developing its own R&D platform. From 2006 to 2010, it commenced independent development of small-molecule new drugs. Between 2011 and 2015, azithromycin tablets were approved in Europe, marking a significant milestone in the Company's globalization efforts. From 2016 to 2020, the Company's Class 1 innovative drug, Dongweien (emtricitabine phosphate), received marketing approval from the NMPA. On the international front, the Company's glargine insulin is currently undergoing overseas clinical trials, and its innovative drug efenitone has obtained U.S. FDA approval for clinical trials. In November 2021, the Company acquired 51.41% of the total share capital of Yichang Dongyangguang Changjiang Pharmaceutical Co., Ltd. ("Dongyangguang Changjiang Pharmaceutical") from Guangdong Dongyangguang Technology Holdings Co., Ltd. On June 21, 2023, the Company was restructured into a joint-stock company, and on August 7, 2025 (the "Listing Date"), it was successfully listed on the Main Board of the Hong Kong Stock Exchange Limited ("HKEX") under the stock code 06887.HK. Since its inception, the Company has consistently adhered to the pharmaceutical philosophy of "serving the Chinese people with higher standards," maintaining a solid industrial foundation and leading competitive advantages in both drug manufacturing and marketing. As of June 30, 2025, the Company operates a nationwide product distribution network in China, supported by 1,888 professional sales personnel. Our sales network covers more than 2,500 tertiary hospitals, over 9,600 secondary hospitals, and more than 89,000 primary hospitals, as well as numerous large-scale national and regional pharmacy chains and other healthcare institutions, enabling us to achieve maximum market coverage across the country. In addition, our overseas sales network spans eight countries and regions, and we maintain long-term sales partnerships with globally renowned pharmaceutical companies, laying a solid foundation for the continued expansion of our international business. One of the Group's core products—Kewei (oseltamivir phosphate)—is a first-line antiviral medication for influenza treatment in China, with its granular formulation being an exclusive patented product of the Company. Oseltamivir phosphate is listed as a "Essential Medicine" on the World Health Organization's Model List of Essential Medicines and is recommended by the U.S. Centers for Disease Control and Prevention as one of the key antiviral agents for treating influenza and avian influenza viruses, including H5N1. In China, oseltamivir phosphate was included in the National Essential Medicines List (2018 Edition) in 2018 and is endorsed as a first-line antiviral agent for influenza treatment in multiple clinical practice guidelines, including the Expert Consensus on Antiviral Treatment of Adult Influenza, the Expert Consensus on Emergency Management of Adult Influenza (2022 Edition), and the Expert Consensus on Diagnosis and Treatment of Pediatric Influenza (2020 Edition). In 2024, the Group's oseltamivir phosphate product was again selected for inclusion in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2024 Edition) issued by the Ministry of Human Resources and Social Security of China.